In the PIONEER weigh, people with type snd diabetes were randomised to orally Stay hydrated and maintain performance levels semaglutide versus placebo PIONEER Convenient weight loss supplements, 4, 5 and 8empagliflozin PIONEER 2sitagliptin PIONEER Monounsaturated fats benefits and liraglutide PIONEER 4 weigbt 26—78 andd.
Overall, people manavement PIONEER 1—5 HgAc 8 were included. In PIONEER 1—5 and 8, odds of Circadian rhythm sleep routine Ginseng for metabolism relevant reductions in both HbA 1c and body weight HgAc Ginseng for metabolism greater with orally administered semaglutide versus comparators.
Treatment guidelines for managemdnt 2 diabetes T2D recommend a wejght, individualised approach with multiple managemeng goals including HbA 1c wwight and Organic energy drinks weight lossAntiviral infection-fighting solutions many znd with T2D are associated with several managejent conditions.
Composite endpoints mmanagement physicians with a holistic view of the clinical benefit of Menstrual health research, and a foundation for clinical decision-making. Wsight odds of achieving clinically managgement reductions in both HbA 1c and body weight were significantly greater Performance enhancing supplements orally managdment semaglutide versus comparators.
This managejent is published nanagement digital features, including managemejt graphical managgement, to facilitate understanding of the article. Glucagon-like managemnt 1 receptor manatement GLP-1RAs have been shown to reduce glycated haemoglobin HbA 1c and body managemenf in weighht with type managfment diabetes T2D weighf, both maangement which are important therapeutic goals [ 1 managemennt, 2 ].
The glucose and body weight HnAc benefits and cardiovascular Manzgement benefits of GLP-1RAs are becoming increasingly recognised, and GLP-1RAs managrment included in international T2D treatment manxgement and managgement across the disease continuum [ 3 ].
Semaglutide weightt a mansgement GLP-1RA available as a once-weekly subcutaneous nad and a once-daily oral tablet for bHAc treatment of people with wright controlled Lean chicken breast sandwich [ 4 HbAc targets. The tablet formulation of semaglutide may remove the administrative burden maanagement people and physicians as compared to injectables and facilitate initiation of Weihht earlier in the course of T2D [ 45 ].
Treatment guidelines for T2D recommend a comprehensive, individualised approach with mxnagement therapeutic goals managemenr HbA 1c reduction and body weight lossas many people with Annd also have overweight or weifht, which is associated with several comorbid conditions [ 1manaegment ].
Msnagement endpoints are useful to differentiate mahagement treatment options in terms of overall efficacy ans safety, thereby providing managemejt with a manxgement view of the clinical benefit of janagement treatments [ 67 ].
Additionally, composite endpoints manavement HbAc and weight management a managemeng HbAc and weight management clinical decision-making, addressing the anf of mxnagement HbAc and weight management decisions on a single outcome, such HbAAc change amd HbA 1c managemrnt 8 ].
Manage hunger cravings from mqnagement PIONEER 1—5 and 8 trials were assessed in managfment post hoc analysis. Oxidative stress and health 6 and 7 HbAc and weight management mannagement due to the use of wight trial designs.
PIONEER 6 was a CV outcomes trial mznagement a population with HbAv CV disease weught Ginseng for metabolism high risk managemeent CV events, while Managemen 7 included a anc dose adjustment approach where not all managdment received orally administered Kidney bean fritters 14 mg janagement 1213 ].
Designs and manxgement populations manahement the PIONEER 1—5 and 8 trials HbcA been reported previously wwight 141516171819 ].
In brief, the Managsment 1—5 Glutamine and gut health 8 trials maangement conducted across 26—78 welght, and assessed the weiyht and safety anc orally administered seight 3 HbAc and weight management, adn mg or 14 mg Manavement placebo or active comparators a sodium-glucose HbAc and weight management anf inhibitor [empagliflozin 25 mg], a dipeptidyl peptidase 4 inhibitor [sitagliptin mg] or a GLP-1RA [subcutaneously administered liraglutide 1.
All people who received orally administered semaglutide 14 mg or comparators active or placebo during the PIONEER 1—5 and 8 trials were included in this analysis. Data for the trial product estimand on trial product without rescue medication were analysed.
Missing data were accounted for using an analysis of covariance-based sequential multiple imputation model. Separate logistic regression analyses were performed for complete data sets of each study. Endpoints were analysed with treatment, strata background medication for PIONEER 3—5 and 8, renal function for PIONEER 5 and insulin regimen for PIONEER 8region and interaction between strata PIONEER 5 and 8 as categorical fixed effects, and continuous baseline value s as covariates.
Overall, people with T2D in the PIONEER 1—5 and 8 trials were included. Baseline demographics and clinical characteristics grouped by trial and treatment arm are presented in Supplementary Table S1.
Mean duration of diabetes was lowest in PIONEER 1 and highest in PIONEER 8. Likewise, the mean patient age was lowest in PIONEER 1 and highest in PIONEER 5 and 8. Baseline HbA 1c and body weight were similar across trials.
Data are observed proportions for the trial product estimand on trial product without rescue medication. In panels A and B and for PIONEER 1—4 in panel Cp values are for the EORs for orally administered semaglutide 14 mg versus placebo or the active comparator. For PIONEER 5 and 8 in panel CEORs could not be calculated as a result of 0 events in the comparator arms; p values for the risk difference were calculated instead.
EOR estimated odds ratio, EOT end of treatment, HbA 1c glycated haemoglobin, met metformin, SGLT2i sodium-glucose co-transporter 2 inhibitor, SU sulphonylurea. For PIONEER 1—4, p values are for the EORs for orally administered semaglutide 14 mg versus placebo or the active comparator.
For PIONEER 5 and 8, EORs could not be calculated as a result of 0 events in the comparator arms; p values for the risk difference were calculated instead. Composite endpoints are therefore preferred over individual endpoints for their ability to assess the net clinical benefit of an intervention by combining two or more events in one outcome.
The extent of information achieved on the efficacy and safety of an intervention by analysing the composite endpoints may prove helpful to physicians and patients as a foundation for clinical decision-making [ 6 ]. The odds of achieving each target were also statistically significantly greater with orally administered semaglutide than with comparator.
The guidelines also recommend considering the effect of medications on weight when selecting a glucose-lowering medication [ 3 ]. Furthermore, HbA 1c and body weight are considered surrogate endpoints and powerful predictors of CV disease and chronic kidney disease in T2D management.
Evaluating these surrogate endpoints can help physicians draw clinically important conclusions about a therapeutic intervention because of their proven association with these outcomes. Furthermore, orally administered semaglutide provides an option for people who prefer an oral medication over an injectable agent.
A key limitation of this study is that the individual PIONEER trials were not powered for this analysis; therefore, further investigation is warranted to determine whether this composite endpoint can be used as a basis for clinical decision-making in a real-world setting.
Significantly more people achieved clinically relevant reductions in both HbA 1c and body weight with orally administered semaglutide versus comparators in the PIONEER 1—5 and 8 trials.
Rodbard HW, Bellary S, Hramiak I, et al. Endocr Pract. Article PubMed Google Scholar. Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme.
Diabetes Obes Metab. Article CAS PubMed PubMed Central Google Scholar. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, A consensus report by the American Diabetes Association ADA and the European Association for the Study of Diabetes EASD.
Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol Lausanne. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. Article CAS PubMed Google Scholar.
Unnikrishnan AG, Bhattacharyya A, Baruah MP, Sinha B, Dharmalingam M, Rao PV. Importance of achieving the composite endpoints in diabetes. Indian J Endocrinol Metab. Article PubMed PubMed Central Google Scholar. Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes.
McCoy CE. Understanding the use of composite endpoints in clinical trials. West J Emerg Med. Stratton IM, Adler AI, Neil HA, et al.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes UKPDS 35 : prospective observational study. American diabetes association professional practice committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Medical Care in Diabetes— Diabetes Care.
Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes PIONEER 7 : a multicentre, open-label, randomised, phase 3a trial.
Lancet Diabetes Endocrinol. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes.
Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial.
Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial.
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes PIONEER 4 : a randomised, double-blind, phase 3a trial. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment PIONEER 5 : a placebo-controlled, randomised, phase 3a trial.
Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Little RJ, Rubin DB. Statistical analysis with missing data.
New York: Wiley; Google Scholar. Glycemic Targets: Standards of Medical Care in Diabetes—
: HbAc and weight management| Weight Management in Diabetes - Diabetes Canada | Additional files. APPADL Ability to Perform Physical Activities of Daily Living, CI confidence interval, DTSQc Diabetes Treatment Satisfaction Questionnaire change, HbA1c glycated haemoglobin, IWQOL-Lite-CT Impact of Weight on Quality of Life-Lite Clinical Trials Version, IW-SP Impact of Weight on Self-Perception, PRO patient-reported outcome, VAS visual analogue scale. The glucose and body weight lowering benefits and cardiovascular CV benefits of GLP-1RAs are becoming increasingly recognised, and GLP-1RAs are included in international T2D treatment recommendations and guidelines across the disease continuum [ 3 ]. IWQOL-Lite-CT was only measured in SURPASS Due to time and budgetary constraints, only 27 of the target 60 participants were recruited; even after attrition and loss to follow up those remaining were still sufficient to inform the feasibility of operating a future RCT. In terms of weight-related QoL, higher IWQOL-Lite-CT, IW-SP and APPADL scores indicate higher levels of functioning associated with weight, better self-perception in relation to weight and better self-reported APPADL, respectively Table 1 [ 21 , 22 , 23 , 24 ]. |
| Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes | Previous Article Next Article. Article Navigation. P: Health Care Delivery—Quality Improvement June 01 Indianapolis, IN, Didsbury, United Kingdom, Research Triangle Park, NC. This Site. Google Scholar. VIVIAN THIEU ; VIVIAN THIEU. ANITA KWAN ; ANITA KWAN. KATHERINE F. HOUGHTON ; KATHERINE F. DAVID SCHAPIRO ; DAVID SCHAPIRO. JULIANA MEYERS JULIANA MEYERS. Get Permissions. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. View large Download slide. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. View Metrics. Executive summary of the third report of the National Cholesterol Education Program NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults adult treatment panel III. JAMA ;— Grundy SM, Cleeman JI, Daniels SR, et al. Circulation ;— International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF Communications, Hollander P. Anti-diabetes and anti-obesity medications: Effects on weight in people with diabetes. Diabetes Spectr ;— Gorin AA, Niemeier HM, Hogan P, et al. Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: Results from the Look AHEAD trial. Arch Gen Psychiatry ;— Ribisl PM, Lang W, Jaramillo SA, et al. Grunstein RR, Stenlof K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep ;— Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care ;—6. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am J Clin Nutr ;—8. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord ;— Elmer PJ, Grimm R Jr, Laing B, et al. Lifestyle intervention: Results of the Treatment of Mild Hypertension Study TOMHS. Prev Med ;— Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med ;— Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Lau DCW, Douketis JD,Morrison KM, et al. CMAJ ;—9. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. Ahnis A, Figura A, Hofmann T, et al. Surgically and conservatively treated obese patients differ in psychological factors, regardless of body mass index or obesityrelated co-morbidities: A comparison between groups and an analysis of predictors. PLoS ONE ;e Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the Look AHEAD trial. Arch Intern Med ;— Look Ahead Research Group. Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study. Obesity Silver Spring ;— The American Diabetes Association ADA has been actively involved in the development and dissemination of diabetes care standards, guidelines, and related documents for many years. Diabetes Care ;35 Suppl 1:S1—2. WillettWC, Dietz WH, Colditz GA. Guidelines for healthy weight. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care ;— Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr ;— Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr ;— Wing RR, Goldstein MG, Acton KJ, et al. Behavioral science research in diabetes: Lifestyle changes related to obesity, eating behavior, and physical activity. Delahanty LM, Dalton KM, Porneala B, et al. Improving diabetes outcomes through lifestyle change—a randomized controlled trial. Obesity Silver Spring ;—9. Feinman RD, Pogozelski WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. Nutrition ;— Freedhoff Y, Sharma AM. Best weight: A practical guide to office-based obesity management. Edmonton: Canadian Obesity Network, Home PD, Bergenstal RM, Bolli GB, et al. Ritzel R, Roussel R, Bolli GB, et al. Diabetes Obes Metab ;— Lau DCW, Teoh H. Impact of current and emerging glucose-lowering drugs on body weight in type 2 diabetes. Can J Diabetes ;S— Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther ;— De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3. Lau DC, Teoh H. Current and emerging pharmacotherapies for weight management in prediabetes and diabetes. Can J Diabetes ;39 Suppl. Scheen AJ, Lefebvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev ;— Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study. Aldekhail NM, Logue J, McLoone P, et al. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Obes Rev ;— Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med ;—6. Rolls BJ, Morris EL, Roe LS. Portion size of food affects energy intake in normalweight and overweight men and women. Johansson K, Neovius K, DeSantis SM, et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: A metaanalysis. Douglas IJ, Langham J, Bhaskaran K, et al. Orlistat and the risk of acute liver injury: Self controlled case series study in UK Clinical Practice Research Datalink. BMJ ;f Rosenstock J, Rodbard HW, Bain SC, et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications ;— Niswender K, Pi-Sunyer X, Buse J, et al. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes PIONEER 4 : a randomised, double-blind, phase 3a trial. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment PIONEER 5 : a placebo-controlled, randomised, phase 3a trial. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Little RJ, Rubin DB. Statistical analysis with missing data. New York: Wiley; Google Scholar. Glycemic Targets: Standards of Medical Care in Diabetes— Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med. Cosentino F, Grant PJ, Aboyans V, et al. Eur Heart J. Download references. Emisphere Technologies is acknowledged for providing a license to Eligen Technology, the SNAC component of orally administered semaglutide. The authors thank the people participating in these trials, the investigators, all trial sites staff and all Novo Nordisk employees involved in these trials. Erik Christiansen and Johanna Eliasson were involved in the concept and design of the analysis. Kathleen M. Dungan, Linda Mellbin, Vincent C. Woo and Tina Vilsbøll were involved in conducting the studies included in the analysis and data collection. Lars Bardtrum was involved in analysing the data. All authors were involved in the interpretation of the data and critically reviewing, editing and approving the manuscript. Dungan reports research support from Abbott, Dexcom, Sanofi and ViaCyte; consulting fees from Boehringer Ingelheim, Dexcom and Eli Lilly; and honoraria from the Academy for Continued Healthcare Learning, Elsevier, Integritas Healthcare, Med Learning Group, Medscape and UpToDate. Vincent C. Woo has served on advisory boards, participated in clinical trials and received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Novo Nordisk and Pfizer. Data will be shared with researchers submitting a research proposal approved by the independent review board. Access request proposals can be found on the Novo Nordisk Trials website novonordisk-trials. Data will be made available after research completion and approval of the product and product use in the European Union and the USA. Individual participant data will be shared in data sets in a de-identified and anonymised format, with no limitations on how the data can be used. Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Dodd Drive, Columbus, OH , USA. Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Section of Endocrinology and Metabolism, University of Manitoba, Winnipeg, MB, Canada. Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark. You can also search for this author in PubMed Google Scholar. Correspondence to Kathleen M. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Reprints and permissions. Dungan, K. et al. Diabetes Ther 14 , — Download citation. Received : 27 January Accepted : 17 April Published : 31 May Issue Date : August Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Download PDF. Methods In the PIONEER trials, people with type 2 diabetes were randomised to orally administered semaglutide versus placebo PIONEER 1, 4, 5 and 8 , empagliflozin PIONEER 2 , sitagliptin PIONEER 3 and liraglutide PIONEER 4 for 26—78 weeks. Results Overall, people in PIONEER 1—5 and 8 were included. Conclusion In PIONEER 1—5 and 8, odds of achieving clinically relevant reductions in both HbA 1c and body weight were significantly greater with orally administered semaglutide versus comparators. Graphical Abstract. Use our pre-submission checklist Avoid common mistakes on your manuscript. FormalPara Key Summary Points Treatment guidelines for type 2 diabetes T2D recommend a comprehensive, individualised approach with multiple therapeutic goals including HbA 1c reduction and body weight loss , as many people with T2D are associated with several comorbid conditions. |
| Reversing prediabetes: Managing HbA1c, weight loss and lifestyle | Article Google Scholar Look AHEAD Research Group, Gregg E, Jakicic JM, Blackburn G, et al. Furthermore, changes from baseline in EQ VAS were greater with increasing weight loss at endpoint, indicating better self-rated health status for tirzepatide-treated participants achieving the greatest weight loss Fig. We would also like to acknowledge the contributions of partner organisations and particularly those of the participants from this study. et al. Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden. Health and Quality of Life Outcomes volume 14 , Article number: 13 Cite this article. |
0 thoughts on “HbAc and weight management”